Severe Aplastic Anemia (SAA) Survey – Eltrombopag

We are looking for individuals with severe aplastic anemia (SAA) and individuals who have been treated with eltrombopag to talk about their experience.

The Canadian Agency for Drugs and Technologies in Health (CADTH) does health technology assessments and makes recommendations about whether federal, provincial and territorial health plans should pay for new drugs. CADTH will soon be reviewing the use of eltrombopag to treat patients with SAA. AAMAC will be making a written submission to ensure that patient voices are represented during the review process and we would like to speak with patients about their experience with SAA.

This survey is important for preparing a submission to influence whether eltrombopag will be paid for by drug insurance plans. Please complete the survey by June 21, 2023.

Please go to to complete the survey.

You do not need to live in Canada to respond to this survey; we appreciate input from every patient.

We are also interested in speaking directly with those who have treatment experience with eltrombopag. Please contact Adam Waiser, who is assisting AAMAC with this work, at if you would be willing to participate in a brief telephone interview.

We would like to thank everyone for helping to ensure that patient experiences are represented in the drug funding review process.